Pharmaceutical companies address MSL best practices

The pharmaceutical industry has struggled recently in supplying Americans with needed medicine and drug companies are now reevaluating relationships between Medical Science Liaisons and stakeholders such as payers and clinical investigators.

An increasing number of biopharmaceutical and medical device companies are finding it more difficult in today's economy for their MSL groups to provide exceptional service. The challenges faced by the industry are causing a strain on all of those associated with the biopharma sector.

Although the role of MSLs has become increasingly important for biopharmaceutical companies, these businesses must be careful to adhere to regulatory requirements. For example, the interactions between MSLs and internal medical staff is subject to legal limitations, which has spurred biopharma companies to explore and define MSL best practices.

A research study entitled "Medical Science Liaison Services Excellence: Generating Value for Diverse Customer Groups" recently was released to explore how biopharm companies operate on a daily basis with regard to MSL groups.

The FDA and the pharmaceutical industry are currently working together to prevent cancer drug shortages around the country, which according to OncLive has been an ongoing concern for 10 years.